Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry

Journal of the American College of Cardiology

Volumn 72, Issue 4, 2018, Pages 351-366

  Greene, Stephen J ^a,b   Butler, Javed ^c   Albert, Nancy M ^d   DeVore, Adam D ^a,b   Sharma, Puza P ^e   Duffy, Carol I ^e   Hill, C Larry ^a   McCague, Kevin ^e   Mi, Xiaojuan ^a   Patterson, J Herbert ^f   Spertus, John A ^g   Thomas, Laine ^a   Williams, Fredonia B ^h   Hernandez, Adrian F ^a,b   Fonarow, Gregg C ⁱ  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f University of North Carolina   (United States)

^g SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^h Mended Hearts   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

dose; medication; reduced ejection fraction; registry

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR; MINERALOCORTICOID ANTAGONIST;

ADULT; AGE; AGED; ARTICLE; COHORT ANALYSIS; DISEASE SEVERITY; DRUG CLASSIFICATION; DRUG INDICATION; DRUG USE; FEMALE; HEART FAILURE WITH REDUCED EJECTION FRACTION; HOSPITALIZATION; HUMAN; HYPOTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; DOSE RESPONSE; DRUG UTILIZATION; HEART FAILURE; HEART STROKE VOLUME; MIDDLE AGED; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REGISTER; SEVERITY OF ILLNESS INDEX; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA; TOTAL QUALITY MANAGEMENT; UNITED STATES;

ADRENERGIC BETA-ANTAGONISTS; AGE FACTORS; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG UTILIZATION; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PRACTICE GUIDELINES AS TOPIC; QUALITY IMPROVEMENT; REGISTRIES; SEVERITY OF ILLNESS INDEX; SOCIOECONOMIC FACTORS; STROKE VOLUME; UNITED STATES;

EID: 85049732013     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2018.04.070     Document Type: Article

References (24)

1. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62 (2013), 147–239.
2. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 70 (2017), 776–803.
3. Fonarow, G.C., Albert, N.M., Curtis, A.B., et al. Incremental reduction in risk of death associated with use of guideline-recommended therapies in patients with heart failure: a nested case-control analysis of IMPROVE HF. J Am Heart Assoc 1 (2012), 16–26.
4. Ouwerkerk, W., Voors, A.A., Anker, S.D., et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J 38 (2017), 1883–1890.
5. Heywood, J.T., Fonarow, G.C., Yancy, C.W., et al. Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF. Circ Heart Fail 3 (2010), 596–605.
6. Owan, T.E., Hodge, D.O., Herges, R.M., Jacobsen, S.J., Roger, V.L., Redfield, M.M., Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355 (2006), 251–259.
7. Fonarow, G.C., Yancy, C.W., Hernandez, A.F., Peterson, E.D., Spertus, J.A., Heidenreich, P.A., Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. Am Heart J 161 (2011), 1024–1030.
8. Fonarow, G.C., Hernandez, A.F., Solomon, S.D., Yancy, C.W., Potential mortality reduction with optimal implementation of angiotensin receptor neprilysin inhibitor therapy in heart failure. JAMA Cardiol 1 (2016), 714–717.
9. Luo, N., Fonarow, G.C., Lippmann, S.J., et al. Early adoption of sacubitril/valsartan for patients with heart failure with reduced ejection fraction: insights from Get With the Guidelines-Heart Failure (GWTG-HF). J Am Coll Cardiol HF 5 (2017), 305–309.
10. Institute of Medicine. Crossing the quality chasm: a new health system for the 21st century. National Academies of Sciences, Engineering, and Medicine. Available at: http://www.nationalacademies.org/hmd/∼/media/Files/Report%20Files/2001/Crossing-the-Quality-Chasm/Quality%20Chasm%202001%20%20report%20brief.pdf. Accessed January 27, 2017.
11. DeVore, A.D., Thomas, L., Albert, N.M., et al. Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registry. Am Heart J 189 (2017), 177–183.
12. Heart Failure Pathway Writing C, Yancy, C.W., Januzzi, J.L. Jr., et al. 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction. J Am Coll Cardiol 71 (2018), 201–230.
13. Steinberg, B.A., Zhao, X., Heidenreich, P.A., et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 126 (2012), 65–75.
14. Smaha, L.A., American Heart A. The American Heart Association Get With The Guidelines program. Am Heart J 148 (2004), S46–S48.
15. Fonarow, G.C., Albert, N.M., Curtis, A.B., et al. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation 122 (2010), 585–596.
16. Gheorghiade, M., Albert, N.M., Curtis, A.B., et al. Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: findings from IMPROVE HF. Congestive Heart Fail 18 (2012), 9–17.
17. Felker, G.M., Anstrom, K.J., Adams, K.F., et al. Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 318 (2017), 713–720.
18. Peterson, P.N., Rumsfeld, J.S., Liang, L., et al. Treatment and risk in heart failure: gaps in evidence or quality?. Circ Cardiovasc Qual Outcomes 3 (2010), 309–315.
19. Khan, M.S., Fonarow, G.C., Ahmed, A., et al. Dose of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and outcomes in heart failure: a meta-analysis. Circ Heart Fail, 10(8), 2017 Aug pii: e003956 https://doi.org/10.1161/CIRCHEARTFAILURE.117.003956.
20. Krum, H., Roecker, E.B., Mohacsi, P., et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS study. JAMA 289 (2003), 712–718.
21. Ruppar, T.M., Cooper, P.S., Mehr, D.R., Delgado, J.M., Dunbar-Jacob, J.M., Medication adherence interventions improve heart failure mortality and readmission rates: systematic review and meta-analysis of controlled trials. J Am Heart Assoc, 5(6), 2016 Jun 17 pii: e002606 https://doi.org/10.1161/JAHA.115.002606.
22. Lappe, J.M., Muhlestein, J.B., Lappe, D.L., et al. Improvements in 1-year cardiovascular clinical outcomes associated with a hospital-based discharge medication program. Ann Intern Med 141 (2004), 446–453.
23. Khan, S.S., Gheorghiade, M., Dunn, J.D., Pezalla, E., Fonarow, G.C., Managed care interventions for improving outcomes in acute heart failure syndromes. Am J Manag Care 14 (2008), S273–S286.
24. Chang, L.L., DeVore, A.D., Granger, B.B., Eapen, Z.J., Ariely, D., Hernandez, A.F., Leveraging behavioral economics to improve heart failure care and outcomes. Circulation 136 (2017), 765–772.